<DOC>
	<DOCNO>NCT02486198</DOCNO>
	<brief_summary>The purpose study determine whether Monosialotetrahexosylganglioside sodium injection relieve neurotoxicity cause oxaliplatin GI cancer .</brief_summary>
	<brief_title>Monosialotetrahexosylganglioside Treatment Oxaliplatin Induced Neurotoxicity Gastrointestinal Cancer</brief_title>
	<detailed_description>Oxaliplatin widely use GI cancer . Neutropenia neurotoxicity common adverse effect oxaliplatin even result discontinue chemotherapy , especially patient suffer heavily acute neurotoxicity.The continuous sense and/or motor abnormal reduce quality life . To date , drug treat oxaliplatin induced neurotoxicity . Monosialotetrahexosylganglioside ( GM ) component membrane nerve cell . Previous phase II clinical trial show , reduce oxaliplatin-induced neurotoxicity ( OIN ) . But investigate cure OIN randomize control trial . A phase III trial need investigate effect safety monosialotetrahexosylganglioside Sodium Injection treatment OIN GI cancer . Investigators design randomized phase III placebo-controlled trail identify effect monosialotetrahexosylganglioside sodium injection treatment agent OIN . Investigators find 2.5 % patient grade 2 serious OIN would relieve 3 month ( data publish ) . Investigators assume monosialotetrahexosylganglioside reduce neurotoxicity 30 % . At level power 0.8 , sample size 160 10 % dropout . The board Tianjin cancer hospital permit trial monitor whole process study . All data submit department clinic trial Tianjin cancer hospital.The statistic specialist participate design afford help data analysis .</detailed_description>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Patients shall normal organic function liver function , Cardiac function renal function ; 2. male female age &gt; 18 year old ; 3. diagnosis GI cancer histology ; 4 . Chronic neurotoxicity grade 2 5 . Karnofsky Performance score 80 6. patient oxaliplatinbased chemotherapy course 21 day last oxaliplatin usage patient discontinue oxaliplatin usage . 7. without uncured tumor except GI cancer , 8 . Patients expect live short 3 month 1. patient receive antineurotoxicity treatment ; 2 . WBC＜4.0×109/L，ANC＜1.5×109/L , PLT＜100×109/L，Hb＜90g/L , TBIL＞1.5Limitation ; BUN）＞1.5Limitation；Cr）＞1.5Limitation；ALT AST＞2.5Limitation（without liver metastasis）；ALT AST）＞5Limitation（with liver metastasis） ; 3. heart dysfunction ; 4. brain metastasis symptom ; 5. peripheral nervous system central nervous system abnormal include diabetes mellitus patient neuropathy ; 6. situation oxaliplatinbased chemotherapy progress , next chemotherapy regime contain agent cause neurotoxicity ( paclitaxel cisplatin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Gastrointestinal cancer</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>neurotoxicity</keyword>
</DOC>